Conclusion:
Screening for COPD using spirometry is likely to identify a predominance of patients with mild to moderate airflow obstruction who would not experience additional health benefits if labeled as having COPD. Hundreds of patients would need to undergo spirometry to defer a single exacerbation. 
C
hronic obstructive pulmonary disease is defined as airflow limitation that is not fully reversible, is gradually progressive, and is associated with an abnormal inflammatory lung response to noxious particles or gases (1) . It currently affects more than 5% of the adult population and is the fourth leading cause of death in the United States. Direct medical and total economic costs of COPD in 1993 were estimated to be $15 billion and $24 billion, respectively (2) .
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) specifies 4 stages of COPD, based on impairment in FEV 1 as measured with spirometry: mild (stage I), moderate (stage II), severe (stage III), and very severe (stage IV) (1) . Patients with stage I disease have FEV 1 of at least 80% of predicted, whereas those with stage IV disease have FEV 1 less than 30% of predicted or FEV 1 less than 50% of predicted and chronic respiratory failure.
Fewer than half of the estimated 24 million Americans with airflow obstruction have actually received a diagnosis of COPD, and diagnosis often occurs in advanced stages of the disease (2) . Because 4 in 5 patients with COPD are current or former smokers, some groups have advocated mass screening of asymptomatic smokers by using office spirometry (3) . Early detection could in theory improve health outcomes by increasing smoking cessation rates; prioritizing administration of influenza and pneumococcal vaccines; and permitting earlier initiation of pharmacologic treatments, oxygen therapy, or pulmonary rehabilitation.
In 2005, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review (2) from the Minnesota Evidence-based Practice Center of the utility of spirometry for case finding, diagnosis, and management of COPD. The report created an opportunity for the U.S. Preventive Services Task Force (USPSTF) to make a timely recommendation on screening for COPD using spirometry. In consultation with the USPSTF, we developed an analytic framework (Figure 1 ) to guide this summary of the evidence on the benefits and harms associated with screening for COPD using spirometry. The key questions were as follows:
1. Does screening for COPD with spirometry reduce morbidity and mortality?
2. What is the prevalence of COPD in the general population? Do risk factors reliably discriminate between high-risk and average-risk populations?
3. What are the adverse effects of screening for COPD with spirometry?
4. Do individuals with COPD detected by screening spirometry have improved smoking cessation rates compared with usual smokers?
5. Does pharmacologic treatment, oxygen therapy, or pulmonary rehabilitation for COPD reduce morbidity and mortality?
6. What are the adverse effects of COPD treatments? 7. Do influenza and pneumococcal immunizations reduce COPD-associated morbidity and mortality?
8. What are the adverse effects of influenza and pneumococcal immunizations in patients with COPD?
METHODS
In addition to summarizing evidence previously synthesized in the 2005 AHRQ report (2) and in 2 subsequent updated reviews (4, 5) , we performed, at the request of the USPSTF, supplemental literature searches for evidence that COPD screening programs reduce morbidity and mortality, evidence of harms from spirometry and COPD treatments, and new evidence on spirometry's use as an independent motivational tool for smoking cessation.
Data Sources
Supplemental searches were limited to Englishlanguage articles identified in PubMed and the Cochrane Library. We searched for studies from 1966 through December 2006 that addressed key questions 1 and 3. We searched for studies published in 2005 and 2006 that addressed key question 4. We searched for systematic reviews published from 1997 through January 2007 that addressed key questions 6, 7, and 8. The Appendix (available at www .annals.org) provides detailed search terms. We identified additional potentially relevant studies by reviewing the reference lists of retrieved articles and consulting with experts.
Study Selection
Two authors independently reviewed all titles, abstracts, and full articles by using explicit inclusion and exclusion criteria for each key question (Appendix, available at www.annals.org). Abstracts that were selected by fewer than 2 reviewers were discussed and selected on the basis of consensus. We considered studies of spirometry regardless of whether the testing was performed in a pulmonary function laboratory or in an office setting.
For questions on benefits of screening and treatment, we included randomized, controlled trials (RCTs); systematic reviews; and meta-analyses. For questions on harms, we also included nonrandomized studies that were generalizable to primary care populations.
Data Extraction and Quality Assessment
Two authors independently reviewed the text of studies selected for full article review to determine whether the studies met eligibility criteria for inclusion. Two authors rated the quality of studies that met inclusion criteria by using established USPSTF methods (Appendix Table 1 , available at www.annals.org). Disagreements in quality rating were resolved by consensus.
Data Synthesis and Statistical Analysis
With 1 exception, data were synthesized qualitatively in narrative and tabular format because of the heterogeneity of patient characteristics, study methods, and/or outcome assessments. Selected health outcomes of COPD treatments were synthesized quantitatively in the 2007 review by Wilt and colleagues (5) but were not further metaanalyzed for this review.
Projected outcomes of population-based screening for COPD using spirometry were estimated by using data on the prevalence of airflow obstruction in the general U.S. population (2) and pooled effectiveness of inhaled therapies at reducing the absolute risk for COPD exacerbations (5) .
Role of the Funding Source
The work of the USPSTF is supported by the AHRQ. This review did not receive separate funding.
RESULTS

Does Screening for COPD with Spirometry Reduce Morbidity and Mortality?
We did not identify any published controlled studies that addressed this question. The 2005 AHRQ report (2) identified populationbased surveys from 7 countries that reported overall prevalence of COPD ranging from 4.5% to 21.1%, depending on the definition used (symptoms necessary or sufficient; American Thoracic Society vs. GOLD criteria) and the population studied.
What Is the Prevalence of COPD in the General
The National Health and Nutrition Examination Surveys (NHANES) I and III characterized the general U.S. population (6, 7) . In NHANES III, 16 084 participants had spirometry; reported detailed medical history information, including previous COPD or an equivalent diagnosis (chronic bronchitis, emphysema); and answered specific questions about the presence of COPD-associated symptoms of cough, phlegm, wheezing, and dyspnea. Among the participants, 7.2% had objectively measured airflow obstruction consistent with the GOLD definition of COPD and 63.3% with airflow obstruction did not report having received a previous diagnosis of COPD. On the other hand, only 17.4% who reported a previous COPD diagnosis had abnormal spirometry result.
The prevalence of COPD increased in older adults and current or past smokers. In NHANES I, the prevalence of severe airflow obstruction not reversible by bronchodilators (corresponding to GOLD stages III or IV) increased from 2.6% in adults age 50 to 59 years to 4.2% in adults age 70 to 74 years. Among current smokers, 2.1% had severe airflow obstruction compared with fewer than 1% of never smokers. Among current smokers, mild or moderate airflow obstruction was nearly 10 times as prevalent as severe airflow obstruction (19.8% vs. 2.1%). Respiratory symptoms did not correlate with the presence or degree of obstruction; 21% of participants with FEV 1 less than 50% of predicted reported no symptoms.
In summary, about 1 in 14 adults in the general U.S. population has objectively measured airflow obstruction consistent with COPD. Evidence suggests that airflow obstruction consistent with COPD is underdiagnosed in primary care; however, basing a COPD diagnosis on symptoms alone leads to overdiagnosis in patients who do not have airflow obstruction. Older adults and current or past smokers are at increased risk for severe disease, but age and smoking status do not reliably discriminate between highand average-risk populations.
What Are the Adverse Effects of Screening for COPD with Spirometry?
We identified 3 articles containing information relevant to this key question. One article evaluated the frequency of cardiac ectopy during spirometry. Two articles examined the theoretical rate of false-positive spirometry results in patients at low risk for airflow obstruction. None of these studies used portable office spirometers.
Fields and colleagues (8) measured the incidence of premature atrial and ventricular contractions during the performance of spirometric flow-volume loops on 42 patients referred to a pulmonary function laboratory. More than half of the patients had a measured FEV 1 -FVC ratio less than 75%, and 18 patients had known cardiac disease. Patients had ambulatory electrocardiographic monitoring for 60 minutes before spirometry, 30 minutes during spirometry, and 60 minutes after spirometry. Cardiac ectopy did not increase during or after spirometry, regardless of patients' histories of pulmonary or cardiac disease.
Hardie and colleagues (9) surveyed a sample of the general population age 70 to 100 years living in Bergen, Norway. Current or former smokers, individuals with previous physician-diagnosed respiratory disease, and individuals with heart disease associated with severe dyspnea were excluded. A randomly selected sample of 208 of the 612 remaining "healthy" persons were invited to participate in a clinical examination that included spirometry. Seventyone participants completed acceptable spirometry. Results indicated that roughly 35% of healthy elderly (age Ͼ70 years) participants tested would receive a diagnosis of at least GOLD stage I COPD (FEV 1 -FVC ratio Ͻ70% and FEV 1 Ͼ80% predicted). This number increased to 50% in participants older than age 80 years. Although the absence of a reference standard made it impossible to determine how many of these apparently healthy persons actually had COPD, Hardie and colleagues concluded that applying strict criteria for airflow obstruction would potentially result in increasing COPD overdiagnosis with increasing age.
Vedal and Crapo (10) recruited 314 healthy adults with characteristics similar to those used to determine reference spirometry values. A total of 251 participants who met inclusion criteria for normal pulmonary function (no history of heart, lung, or chest-wall disease; no history of cigarette smoking; normal chest radiography; and normal heart and lung examinations) had pulmonary function tests, including simple spirometry (FVC, FEV 1 , and FEV 1 -FVC ratio). Ten percent had at least 1 abnormal spirometric result. These findings were used to develop COPD diagnostic criteria requiring 2 abnormal spirometry measurements that do not differ from each other by more than 5%; currently, therefore, only 1 abnormal spirometry measurement would not result in a COPD diagnosis.
In summary, no evidence suggests that spirometry causes any clinically significant adverse effects. However, data suggest that a baseline percentage of false-positive results occurs in asymptomatic healthy persons.
Do Individuals with COPD Detected by Screening Spirometry Have Higher Smoking Cessation Rates Than Usual Smokers?
The 2005 AHRQ report (2) systematically reviewed RCTs that evaluated spirometry as a motivational tool for smoking cessation, independently or in combination with behavioral and pharmacologic therapies. Wilt and colleagues (4) updated their literature search through October 2005 in a subsequent article. Seven RCTs containing 6052 participants met inclusion criteria. Outcomes included self-reported and biologically verified abstinence rates, sustained abstinence over the course of the study, and number of quit attempts. Follow-up ranged from 9 to 36 months. In general, participants in both the intervention and control groups received smoking cessation counseling.
Absolute improvements in abstinence rates in the included trials varied from 1% to 33%. Although 4 trials showed statistically significant results in favor of the smoking cessation intervention, the independent effect of spirometry could not be assessed. Only 1 trial evaluated spirometry independently from pharmacologic therapies proven to increase cessation rates (nicotine replacement, bupropion). This trial, which required a separate appointment outside of the primary care setting for spirometry, showed a statistically insignificant 1% improvement in patient-reported abstinence at 12 months (11).
Our supplemental literature search identified 1 systematic review and 1 fair-quality RCT in addition to the 2005 AHRQ report (2). Bize and associates (12) reviewed RCTs on the efficacy of "biomedical risk assessment and feedback" to improve smoking cessation rates. Measurements included exhaled carbon monoxide, spirometry, genetic testing, and carotid and femoral ultrasonography. The initial literature search retrieved 4049 references. Eight trials met inclusion criteria; 4 of these used spirometry as one of the elements. The only RCT not included in the 2005 AHRQ report used spirometry in combination with exhaled carbon monoxide measurements and found a statistically insignificant improvement (odds ratio, 2.45 [95% CI, 0.73 to 8.25]) in biochemically measured abstinence in the intervention group after 6 months (13).
Buffels and colleagues (14) recruited 221 adult smokers from 16 general practices in Belgium. Willingness to quit smoking, assessed by their primary care physician, was required for study eligibility. Comparability of study groups was not clear, because patient characteristics other than sex and smoking status were not reported. All participants were prescribed nicotine replacement therapy, bupropion, or both and were then randomly assigned to a group that had spirometry in the office or to a control group that did not have spirometry. Participants were contacted at 6, 12, and 24 months thereafter to determine whether they had or had not resumed smoking. Those who reported sustained abstinence after 2 years had urine testing to verify cessation. Differences in quit rates between the intervention and control groups were not statistically significant.
In summary, the evidence on spirometry as an independent motivational tool for smoking cessation is inconclusive. Most studies have at least 1 of the following important limitations: did not evaluate spirometry independently from other therapies known to improve smoking cessation rates, insufficient sample size to detect a statistically significant effect, and heterogeneity of interventions and outcome measures that precludes pooling of data in a meta-analysis. Eligible treatments included long-acting ␤-agonists, short-and long-acting anticholinergics, inhaled corticosteroids, and combinations of these medications. "Rescue" treatments, such as short-acting ␤-agonists, were not reviewed. Included studies enrolled patients with COPD; had more than 50 participants in each group (intervention therapy vs. placebo or active control); had a duration of at least 3 months; and provided outcomes data on COPD exacerbations, health status, and hospitalizations and/or mortality.
A total of 43 RCTs and 10 meta-analyses met inclusion criteria. Most trials involved patients with disabling respiratory symptoms and severe or very severe airflow obstruction (FEV 1 Ͻ50% predicted). Because of the very limited number of patients with mild or moderate COPD and the trial designs, treatment effectiveness by severity of disease could not be evaluated.
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Of the outcomes reviewed, the evidence that inhaled therapies for COPD decreased exacerbations was most complete and compelling. Monotherapy with any of 3 of the 4 major classes of inhaled COPD therapies (longacting ␤-agonists, long-acting anticholinergics, and corticosteroids) decreased the risk for at least 1 exacerbation more than placebo (relative risk reduction, 13% to 17%; absolute risk reduction, 4% to 6%). Short-acting anticholinergics did not reduce exacerbations more than placebo.
Nine trials evaluated combination therapy. Six trials compared inhaled corticosteroids plus long-acting ␤-agonists with placebo or monotherapy with 1 of the component medications. In a pooled analysis of the 5 published studies, the absolute risk reduction in patients having at least 1 exacerbation for combination therapy was 6% (CI, 1% to 12% Long-acting anticholinergics reduced the proportion of patients who required hospitalization for COPD more than placebo (absolute risk reduction, 2% [CI, 1% to 4%]). On the other hand, 3 trials that evaluated longacting ␤-agonists versus placebo did not find a statistically significant difference in the proportion. Similarly, the Lung Health Studies I and II (which enrolled patients with mild to moderate disease) found no difference in hospitalizations per 100 person-years of exposure in patients receiving ipratropium or inhaled corticosteroids (15) .
A meta-analysis of retrospective patient-level data from trials of inhaled corticosteroids versus placebo demonstrated an absolute reduction of 1% in all-cause mortality after 1 year (16). This effect was most pronounced in subgroups of women and former smokers but was not present in patients with mild to moderate disease (FEV 1 Ͼ60% predicted).
Subsequent to this meta-analysis, Calverley and colleagues (17) conducted a fair-quality RCT that compared all-cause mortality in patients taking combination salmeterol-fluticasone, salmeterol alone, fluticasone alone, or placebo over 3 years in patients with COPD who had FEV 1 less than 60% of predicted. A total of 6112 current or former smokers between 40 and 80 years of age were recruited from outpatient centers in 42 countries. Whether recruitment occurred in primary care settings, referral centers, or a combination of both was not clear. Patients had had 1 previous COPD exacerbation on average; data on length of time since COPD diagnosis and duration of previous pharmacologic therapy were not provided. The relative risk reduction in all-cause mortality in the combination therapy group approached but did not reach statistical significance (odds ratio, 0.825 [CI, 0.681 to 1.002]) compared with the placebo group.
Oxygen Therapy
Two trials of patients with very severe COPD (FEV 1 (18, 19) . No trials to date have evaluated the effect of supplemental oxygen on any health outcome in patients with less severe disease.
Pulmonary Rehabilitation
Two previous systematic reviews (20, 21) of rehabilitation programs incorporating exercise training, education, behavioral modification, and outcome assessment found improvements of borderline clinical significance in health status but no effect on mortality in patients with severe COPD. A more recent systematic review and meta-analysis (22) of 31 RCTs found clinically significant improvements in dyspnea, fatigue, emotional function, and patients' sense of control over their condition on the Chronic Respiratory Disease Questionnaire and statistically significant improvements on the St. George Respiratory Questionnaire that did not reach clinical significance.
Summary
Pharmacologic treatments modestly reduce exacerbations in patients with symptomatic severe COPD and may have a small absolute effect on all-cause mortality. However, the strongest evidence for a mortality benefit comes from an RCT involving patients with a previous exacerbation who would not have received a diagnosis with screening. Oxygen therapy reduces mortality in patients with very severe COPD and resting hypoxia. Pulmonary rehabilitation improves health status measures in selected patients.
These conclusions are limited by the absence of patients with mild or moderate COPD in most therapeutic trials. In addition, none of these therapies has been tested in patients with airflow obstruction who do not recognize or report symptoms.
What Are the Adverse Effects of COPD Treatments?
Wilt and colleagues (5) reported on adverse effects of COPD medications that occurred in RCTs. Inhaled corticosteroids increased the frequency of oropharyngeal candidiasis, throat irritation, and easy bruising and decreased lumbar spine and femur bone density. Tiotropium increased the frequency of dry mouth. A meta-analysis of 20 RCTs (23, 24) found that ␤-agonists increased the preva-
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Screening for Chronic Obstructive Pulmonary Disease Using Spirometry www.annals.orglence of sinus tachycardia and major and minor cardiovascular events. A large recent RCT of COPD therapy found no differences in cardiovascular events between patients using a long-acting ␤-agonist and control participants; this trial also found no differences in fractures between patients using an inhaled corticosteroid and control participants (17) . Using these known adverse effects to inform our literature search, we identified 12 systematic reviews of fair to good quality published since 1997 (Appendix Table 2 , available at www.annals.org). Appendix Table 3 (available at www.annals.org) summarizes their findings by drug class.
For short-acting inhaled ␤ 2 -agonists, no adverse events have been reliably noted in RCTs because of short duration and small sample sizes (25) . Long-acting inhaled ␤ 2 -agonists have several cardiovascular effects. A single dose increases heart rate and serum potassium concentration (24) . One review of RCTs found a statistically significant higher risk for cardiovascular events (24) , whereas another showed no statistically significant difference in incidence or time to first cardiovascular event (26) . In case-control studies, long-acting inhaled ␤ 2 -agonist use has been associated with an increased risk for myocardial infarction, heart failure, cardiomyopathy, and unstable angina (23) . One review of RCTs found an increased risk for respiratory death with long-acting inhaled ␤ 2 -agonist use compared with placebo (27) ; however, Wilt and colleagues could not reproduce these findings in their 2007 review (5) . A subsequent large RCT did not find a statistically significant difference in mortality in patients taking a long-acting ␤-agonist (17).
Reviews of inhaled anticholinergics compared with placebo found statistically significant increases in dry mouth, urinary tract infections, and urinary retention (28, 29) . Results for cardiovascular events varied. In 1 review, the evidence could not be reliably summarized because of the heterogeneity of RCT results (29) . Another review found no statistically significant difference in incidence of cardiac arrest or myocardial infarction; however, risks for tachycardia and dysrhythmias were higher (28) . In comparisons of placebo, ipratropium, and salmeterol, no statistically significant difference in cardiovascular or all-cause mortality was observed (28 -30) .
Reviews of inhaled corticosteroids compared with placebo found statistically significant increased risks for oropharyngeal candidiasis and skin bruising (31, 32) . Bone mineral density effects varied. One review reported no effect (33), whereas other reviews were inconclusive because of short study duration and small sample sizes. Case-control studies suggested an increased risk for fractures, openangle glaucoma, and cataracts; these effects seemed to be small and infrequent. A large RCT found a statistically significant increased risk for pneumonia in patients using fluticasone after 3 years (17) .
In summary, minor adverse effects are commonly associated with inhaled COPD treatments. The evidence regarding major adverse effects (such as fractures, cardiovascular events, and mortality) is mixed and inconclusive.
Do Influenza and Pneumococcal Immunizations Reduce COPD-Associated Morbidity and Mortality? What Are the Adverse Effects of Influenza and Pneumococcal Immunizations in Patients with COPD?
Two systematic reviews in the Cochrane Library (34, 35) provided information on these key questions. Both reviews identified RCTs of the respective vaccines in patients with COPD from the Cochrane Airways Group specialized register of trials (derived from systematic searches of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and CINAHL databases) and hand searches of respiratory journals and meeting abstracts. The influenza vaccination reviewers searched for trials through May 2006, and the pneumococcal vaccination reviewers searched through April 2006. Trials recruited patients with a representative range of COPD severity from mild to very severe, but few trials stratified results by disease severity.
The influenza vaccination review (34) included 11 fair-to good-quality RCTs that reported exacerbation rates, hospitalizations, mortality, lung function, and adverse effects. Six trials involved only patients with COPD. Data comparing exacerbation rates between vaccinated and unvaccinated patients were extracted from 2 studies involv- * Screening and treatment assumptions were as follows: 1) The true prevalence of FEV 1 Ͻ50% of predicted, in subgroups of the general primary care population, is that measured in the Third National Health and Nutrition Examination Survey (7); 2) inhaled therapies only benefit patients with FEV 1 Ͻ50% of predicted; 3) treatment consists of the combination of an inhaled ␤-agonist and an inhaled corticosteroid; 4) patients who do not recognize or report symptoms have similar benefit to that of symptomatic patients; 5) treatment produces a 6% absolute risk reduction in patients having Ն1 COPD exacerbation over 6 -36 mo (as in the 2007 review by Wilt et al. [5] ); 6) because a COPD exacerbation causes a patient to seek medical care, leading to a clinical diagnosis, the incremental benefit of screening over clinical detection is limited to avoidance of a single exacerbation. COPD ϭ chronic obstructive pulmonary disease; NNS ϭ number needed to screen. † These patients were therefore eligible to receive inhaled therapies. . When data were stratified into "early" (within 4 weeks of vaccination) and "late" (after 4 weeks) exacerbations, decreases in the latter were responsible for almost the entire effect. Vaccinated and unvaccinated groups did not statistically significantly differ in lung function, hospitalizations, or mortality. Influenza vaccination, compared with placebo, was associated with a statistically significant increase in local reactions at the injection site across all included studies. Other adverse effects, including increases in wheezing, upper respiratory tract symptoms, malaise, and myalgia, were generally mild and transient and were not consistently observed.
The pneumococcal vaccination review (35) included 4 RCTs of varying quality with a total of 937 patients. Only studies limited to patients with COPD were included. One study of 49 patients provided data on exacerbations; this study did not show a statistically significant difference in this outcome between vaccinated and unvaccinated patients (odds ratio, 1.43 [CI, 0.31 to 6.69]). No statistically significant benefits of pneumococcal vaccination in patients with COPD were observed for secondary end points of pneumonia, emergency department visits, hospitalizations, or mortality. One of the included studies showed a trend toward pneumonia protection in a subgroup of vaccinated patients with FEV 1 less than 40% predicted (odds ratio, 0.47 [CI, 0.22 to 1.01]) (36) . The other 3 studies did not report data by COPD severity.
None of the studies on pneumococcal vaccine reported quantitative data on disability, change in lung function, or adverse effects.
In summary, influenza vaccination reduces exacerbations in patients with COPD; evidence regarding benefits of pneumococcal vaccination is insufficient. Whether benefits vary according to severity of COPD is uncertain, and these data do not support prioritizing vaccination on the basis of spirometric measurements. Both vaccines seem to be well tolerated. Table 1 shows the hypothetical outcomes of a spirometry screening program targeting various U.S. population subgroups, defined by smoking status and age. These cal- What is the prevalence of COPD in the general population? Do risk factors reliably discriminate between high-risk and average-risk populations?
Projected Outcomes from Screening for COPD Using Spirometry
Population-based surveys (including NHANES) from 7 countries NHANES I and III (6, 7) Prevalence is 4.5% to 21.1%, depending on COPD definition, and is 7.2% in the U.S. population using the GOLD definition. Severe airflow obstruction is higher in older adults and in current and past smokers. What are the adverse effects of screening for COPD with spirometry?
3 small studies of spirometry performed in pulmonary function laboratories Spirometry seems to be physically safe; some false-positive test results occur in asymptomatic patients. Do individuals with COPD detected by screening spirometry have improved smoking cessation rates compared with usual smokers?
8 RCTs and 2 systematic reviews with up to 36 months of follow-up; only 2 RCTs evaluated the independent motivational effect of spirometry Spirometry does not seem to increase smoking cessation rates, but further studies may be needed.
Does pharmacologic treatment, oxygen therapy, or pulmonary rehabilitation for COPD reduce morbidity and mortality? culations were based on NHANES data on the prevalence of FEV 1 less than 50% of predicted and on the absolute risk reduction in COPD exacerbations from inhaled treatments, as reported in Wilt and colleagues' review (5). We made an untested assumption that patients with airflow obstruction who do not recognize or report symptoms would benefit to the same degree as patients with symptoms studied in the clinical trials. Making this assumption allowed the USPSTF to estimate the upper bound, or maximum benefit, that might be achieved through early detection and treatment of these patients. Figure 2 shows a sample calculation of the number of patients needed to screen if population-based screening were applied to current smokers older than age 40 years, as some groups (3) have advocated.
DISCUSSION
No direct evidence indicates that screening patients for COPD using spirometry improves long-term health outcomes ( Table 2 ). An evaluation of the potential benefits of such screening depends on piecing together a coherent chain of evidence. One impetus for screening has been data from population surveys showing that a substantial number of smokers with severe airflow obstruction do not recognize or report respiratory symptoms to a physician. However, these prevalence data also show that more than 90% of patients with undetected airflow obstruction have FEV 1 50% of predicted or greater. This information is important because the efficacy of COPD pharmacologic treatments has been established only in symptomatic patients with FEV 1 less than 50% of predicted.
Pharmacologic treatments for COPD have been demonstrated to reduce the absolute risk for 1 or more COPD exacerbations by 4% to 6% in pooled analyses. Although a recent RCT suggested that these treatments also reduce mortality to a smaller degree, that trial was conducted in a sample of symptomatic patients, most of whom had already experienced exacerbations and would have received a diagnosis clinically rather than with screening. No studies to date permit an estimate of the incremental mortality benefit from treating patients who would not have received a diagnosis clinically.
The hypothesis that knowing one's spirometry results might provide extra motivation for a smoker to quit has not been tested adequately. Previous trials have not assessed the independent effect of spirometry as part of a comprehensive smoking cessation program that includes proven pharmacologic therapies. However, data suggest that even if spirometry provides an incremental benefit over other cessation strategies, the benefit is likely to be small.
Individuals with mild to moderate airflow obstruction may benefit from receiving an annual influenza vaccine, although how much of the overall reduction in COPD exacerbations applies to this subgroup is uncertain. The incremental benefit is likely to be small because most patients with COPD are older than 50 years of age and would already be targeted to receive the vaccine.
These potential benefits must be weighed against potential harms. Although studies conducted in pulmonary function laboratories have demonstrated little risk of spirometry causing physical harm, widespread screening of adult smokers (most of whom do not have airflow obstruction) is likely to produce some false-positive results. Pharmacotherapy is commonly associated with minor adverse effects and, rarely, with major events.
In conclusion, screening for COPD using spirometry is likely to identify a predominance of patients with mild to moderate airflow obstruction who would not experience additional health benefits if labeled as having COPD. A few individuals with severe airflow obstruction (FEV 1 Ͻ50% of predicted) might benefit from pharmacologic treatments that reduce exacerbations. Hundreds of patients would need to have screening spirometry to identify 1 person with COPD whose incremental health benefit over clinical diagnosis would probably be limited to the avoidance of a first exacerbation. Clinical Guidelines Screening for Chronic Obstructive Pulmonary Disease Using Spirometry generously sharing data that were not yet published when this review was written. They also thank Caryn McManus and Gloria Washington at the AHRQ for technical assistance with the literature searches and compilation of data. language studies published from 1966 through December 2006, using combinations of the MeSH terms spirometry, diagnostic errors, and adverse effects. We considered studies of spirometry regardless of whether the testing was performed in a pulmonary function laboratory or in an office setting. We excluded articles that were narrative reviews, letters, or editorials; included only a sample that did not have COPD (for example, children with cystic fibrosis); or did not address harms or test characteristics of spirometry. We also excluded isolated case reports documenting spirometry-induced pneumomediastinum, bronchial obstruction, or incarcerated inguinal hernia. We had determined a priori to exclude articles that compared the diagnostic accuracy of spirometry performed in primary care settings with that performed in referral settings (with referral settings serving as the "gold standard"). No articles of this type were retrieved by the search.
Two reviewers independently reviewed the title lists, abstracts, and full articles. Disagreements were resolved by consensus.
The initial literature search retrieved 59 articles, which were entered into an EndNote database (Thomson ResearchSoft, Philadelphia, Pennsylvania). We excluded 27 articles at the title stage; after a review of the remaining abstracts, we excluded 23 additional articles. The remaining 9 articles were obtained for fulltext review; 7 more articles were excluded at this stage. One article was identified from reviewing the reference list from an excluded article, leaving 3 articles included in this review. Appendix Figure 1 shows the flow of the literature search.
Key Question 4
We searched PubMed for systematic reviews and RCTs of spirometry as a motivational tool for smoking cessation published in 2005 and 2006, using a search strategy identical to that of the 2005 AHRQ report (2) . We excluded studies that had follow-up less than 6 months or had fewer than 25 participants per treatment group or if the control group received spirometric results. Two reviewers independently reviewed the title lists, abstracts, and full articles. Disagreements were resolved by consensus.
The initial literature search returned 42 articles, which were entered into an EndNote database. We excluded 36 articles at the title or abstract stage; the remaining 6 articles were obtained for full-text review. We excluded 3 more articles at this stage. One of the remaining 3 articles was the 2005 AHRQ report (5); the other 2 articles are included in this review. Appendix Figure 2 shows the flow of the literature search.
Key Question 6
We searched PubMed to identify English-language systematic reviews of adverse effects of COPD medications published from January 1997 through January 2007, using the MeSH terms pulmonary disease and chronic obstructive/drug therapy, and combinations of MeSH terms and text words representing adverse effects noted in the RCTs of therapy included in Wilt and colleagues' 2007 systematic review (5) . Two reviewers reviewed the titles. Studies were excluded if they were not systematic re-views; discussed medications other than ␤-agonists, anticholinergics, or inhaled corticosteroids; were older versions of the same publication (such as Cochrane reviews); or had no relevant outcomes.
The initial literature search returned 50 articles, which were entered into an EndNote database. We excluded 38 articles at the title stage. Two reviewers independently reviewed the full text of the remaining 12 articles, all of which met inclusion criteria for this review. Appendix Figure 3 shows the flow of the literature search.
Key Question 7
We searched the Cochrane Database of Systematic Reviews for completed reviews of the benefits of influenza and pneumococcal vaccinations in patients with COPD. One review on each vaccination was identified and included in the review.
Key Question 8
We searched PubMed to identify English-language systematic reviews published from January 1997 through January 2007, using combinations of the MeSH terms and text words pneumococcal vaccine, influenza vaccine, adverse effects, harms, and safety. The initial literature search returned 3 articles. Two of these articles had already been retrieved for key question 7, and the third article was a previous version of 1 of these articles.
